Talk:Pexastimogene devacirepvec
Latest comment: 8 years ago by Rod57 in topic Out of date
This is the talk page for discussing improvements to the Pexastimogene devacirepvec article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||
|
We should probably move/rename this to Pexa-vec soon
editPexa-vec ? or would pexastimogene devacirepvec be the INN ? - Rod57 (talk) 09:35, 10 May 2013 (UTC)
- You are right, this page will need moving to pexastimogene devacirepvec, can create a redirect to there from Pexa-vec, this would be in-keeping with talimogene laherparepvec. Viraltonic (talk) 11:12, 10 May 2013 (UTC)
- Done - Rod57 (talk) 18:45, 14 October 2016 (UTC)
Out of date
editArticle gives status as of Aug 2011 but the phase III trial failed its primary endpoint in 2013 and the company website gives the March 2014 development plan. - Rod57 (talk) 23:04, 14 November 2014 (UTC)
- Website also says "A Phase 2b study (TRAVERSE) was also initiated in HCC patients whose disease had progressed on or following treatment with sorafenib or who could not tolerate that treatment. In September 2013, Transgene announced that the TRAVERSE study did not meet its primary endpoint of overall survival in this challenging-to-treat patient population. Therefore, Pexa-Vec will not be further developed as a second-line treatment for HCC but only in the first-line indication." - Rod57 (talk) 18:55, 14 October 2016 (UTC)
RR gene also deleted
editThe ribonucleotide reductase gene (aka RNR) may also be deleted - implied by Oct2016 ref, but not mentioned by Cripe2015. - Rod57 (talk) 18:47, 14 October 2016 (UTC)